Opioid switch to oral methadone in cancer pain

Current Opinion in Oncology

Volumn 12, Issue 4, 2000, Pages 308-313

  Mancini, Isabelle ^a   Lossignol, Dominique A ^a   Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE;

ANALGESIC ACTIVITY; CANCER PAIN; CONFUSION; DELIRIUM; HUMAN; MYOCLONUS; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHADONE; MORPHINE; NEOPLASMS; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0034508676     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200007000-00006     Document Type: Review

References (50)

1. The treatment of cancer pain
2. Opioid rotation for cancer pain
3. Opioid rotation in patients with cancer pain
4. Opioid analgesic for cancer pain: Toxicities and their treatment
5. Opioid rotation (OR) for toxicity reduction in terminal cancer patients
6. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators
7. CNS adverse effects of opioids in cancer patients: Guidelines for drug treatment
8. Individual variability in the response to different opioids: Report of five cases
9. A comparative study of the efficacy and the pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer
10. Rectal methadone in cancer patients with pain: A preliminary clinical and pharmacokinetic study
11. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain
12. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients
13. An update on the clinical use of methadone for cancer patients
14. Role of methadone in the management of pain in cancer patients
15. The use of methadone in the care of the dying
16. Opioid toxicity
17. Opioid hyperexcitability: The application of alternative opioid therapy
18. Morphine-3-glucoronide: A potent antagonist of morphine analgesia
19. The excitatory effects of opioids
20. Opiate alkaloids antagonize postsynaptic glycine and GABA responses: Correlation with convulsant action
21. Nonmetabolic environmental toxicants: Air pollutant, solvents and vapors, and pesticides
22. Myoclonic seizure activity with chronic high-dose spinal opioid admisnistration
23. Inadvertent intrathecal use of ionic contrast media for myelography
24. Methadone in the management of cancer pain: A review
25. Clinical pharmacokinetics of methadone
26. Estimation of methadone clearance: Application in the management of cancer pain
27. Pharmacokinetics and pharmacodynamics of methadone infusions in patients with cancer pain
28. Increase of alpha-1-acid glycoprotein after treatment with amitriptyline
29. Guidance for clinicians in discerning and comparing the price of pharmaceutical agents
30. Effective pain relief in cancer patients using methadone at extended dosing intervals
31. N-methyl-d-aspartate (NMDA) receptors, mu and kappa opioid tolerance and perspectives on new analgesic drug development
32. Opioid type and other clinical predictors of laxative dose in advanced cancer patients
33. Methadone plasma protein binding: Alterations in cancer and displacement from alpha 1-acid glycoprotein
34. Dose ratio between morphine and methadone in patients with cancer pain
35. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences
36. Patient-controlled dose regimen of methadone for chronic cancer pain
37. Pharmacokinetic basis for optimal methadone treatment in cancer patients
38. Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: Clinical and economic considerations
39. Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone and morphine
40. Disappearance of morphine-induced hyperalgesia after discontinuing or subsituting morphine with other opioid agonists
41. Patient-controlled analgesia with oral methadone in cancer pain: Preliminary report
42. Severe opioid toxicity and somatization of pyschological distress in a cancer patient with a background of chemical dependence
43. Use of methadone in a highly tolerant patient receiving palenteral hydromorphone
44. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high dose morphine
45. Clinical efficacy of methadone in patients refractory to other μ-opioid receptor agonist analgesics for the management of terminal cancer pain
46. Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio?
47. Cancer Pain
48. Rapid switching from morphine to methadone in cancer patients with poor response to Morphine
49. Methadone in pain uncontrolled by morphine